Objective: To explore the clinical feature, therapeutic effect and prognosis of isolated methylmalonic acidemia.
Methods: The clinical characteristics, laboratory findings, treatment and outcome of 40 patients were retrospectively analyzed. The main treatment was a low-protein diet supplemented with L-carnitine and special milk free of leucine, valine, threonine and methionine. Vitamin B12 was also given to cobalamin responders. The patients were followed up every 1-3 months.
Results: Mutations in the MUT gene were identified in 30 of 33 patients who had accepted DNA testing. Thirty cases were treated and followed up regularly for from 1 month to 8 years. Eight cases had died, 8 had developed normal intelligence, among whom 4 from newborn screening were asymptomatic. Psychomotor developmental delay and mental retardation were present in 14 cases. The propionylcarnitine level, ratio of propionylcarnitine/acetylcarnitine in blood, methylmalonic acid and methylcitric acid levels in urine have decreased significantly, with the median values reduced respectively from 24.15 (7.92-81.02) μmol/L, 1.08 (0.38-6.01), 705.34 (113.79-3078.60) and 7.71 (0.52-128.21) to 10.50 (3.00-30.92) μmol/L, 0.63 (0.25-2.89), 166.23 (22.40-3322.21) and 3.96 (0.94-119.13) (P < 0.05).
Conclusion: The prognosis of isolated methylmalonic acidemia may be predicted with the enzymatic subgroup, age at onset and cobalamin responsiveness. Outcome is unfavorable in neonatal patients and those who were non-responsive to cobalamin.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3760/cma.j.issn.1003-9406.2013.05.018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Mutation spectrum and genotype-phenotype correlation of pediatric patients with methylmalonic acidemia.
Pediatr Res
November 2024
Changzhou Maternity and Child Health Care Hospital, Nanjing Medical University, Changzhou, 213000, China.
Background: MMA incidence is significantly greater in China than in the rest of the world, but the mutation spectrum of MMA in China has not yet been mapped.
Methods: We summarized published MMA-related articles and conducted a systematic meta-analysis of the literature.
Results: We analyzed the gene variants information of 926 pediatric MMA patients in China; 517 were children with combined MMA, and 409 were children with isolated MMA.
Isolated methylmalonic acidemia in Mexico: Genotypic spectrum, report of two novel MMUT variants and a possible synergistic heterozygosity effect.
Mol Genet Metab Rep
December 2024
Departamento de Patología, Instituto Nacional de Pediatría, Mexico.
Isolated methylmalonic acidemia (iMMA) is a group of monogenic metabolic disorders affecting methylmalonate and cobalamin metabolism. Five iMMA-responsible genes have been described to date: (MIM *609058), (MIM *607481, (MIM *607568), (MIM *611935), and (MIM *608419). Although iMMA is the most common form of organic acidemia reported in Mexico, its genotypic spectrum is still largely unknown.
View Article and Find Full Text PDFRenal Replacement Therapy in Methylmalonic Aciduria-Related Metabolic Failure: Case Report and Literature Review.
J Clin Med
July 2024
Nephrology, Dialysis and Transplant Unit, Department of Medicine, Padova University Hospital, University of Padova, 35128 Padua, Italy.
Article Synopsis
- Methylmalonic Aciduria (MA) is a rare disorder that leads to toxic methylmalonic acid buildup, causing serious health issues like metabolic crises and kidney damage.
- A case study of a 39-year-old male with MA and stage IV chronic kidney disease illustrates how a single hemodialysis session effectively treated his acute metabolic crisis after a gastrointestinal infection.
- Long-term management of MA often requires continuous kidney and/or liver transplantation, with combined liver-kidney transplants offering better outcomes due to reduced acid production and improved kidney function.
Improved therapeutic efficacy in two mouse models of methylmalonic acidemia (MMA) using a second-generation mRNA therapy.
Mol Genet Metab
October 2024
Rare Diseases, Moderna, Inc., Cambridge, MA 02139, USA.
Isolated methylmalonic acidemia/aciduria (MMA) due to MMUT enzyme deficiency is an ultra-rare pediatric disease with high morbidity and mortality, with no approved disease-altering therapies. Previous publications showed that systemic treatment with a codon-optimized mRNA encoding wild-type human MMUT (MMUT) is a promising strategy for treatment of MMA. We developed a second-generation drug product, mRNA-3705, comprised of an mRNA encoding the MMUT enzyme formulated in a lipid nanoparticle (LNP) with incorporation of enhancements over the previous clinical candidate mRNA-3704.
View Article and Find Full Text PDFClinical outcomes of patients with mut-type methylmalonic acidemia identified through expanded newborn screening in China.
Hum Genomics
July 2024
Department of Pediatric Endocrinology/Genetics, Shanghai Institute for Pediatric Research, Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Article Synopsis
- Isolated methylmalonic acidemia, often caused by mutations in the methylmalonyl-CoA mutase gene, can be detected through newborn screening (NBS) or clinically after onset, and this study compares outcomes between these methods of diagnosis.
- The analysis included 168 patients diagnosed via NBS and 210 diagnosed clinically, evaluating factors like age at diagnosis, treatment response, and long-term outcomes.
- Results indicated that NBS-detected patients had better prognoses, including earlier diagnosis, improved treatment response, and reduced disease onset, suggesting that NBS improves survival rates for infants with this condition.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!